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Transient receptor potential melastatin-4 channel (TRPM4) dysregulation
contributes to heart conditions, immune diseases, and cervical and prostate
cancer. Up to now, the involvement of TRPM4 in colorectal cancer (CRC)
pathophysiology remains unknown. Here, we investigated tumor tissue
microarrays from 379 CRC patients and analyzed TRPM4 protein expres-
sion, tumor characteristics, and clinical outcome. High TRPM4 protein
expression was associated with unfavorable tumor features characteristic
for epithelial–mesenchymal transition and infiltrative growth patterns, that
is, a high number of tumor buds and a low percentage in tumor border
configuration. Compared to CRC cells representing early cancer stages,
TRPM4 protein expression was the highest in cells representing late-stage
metastatic cancer. Investigation of CRC cell line HCT116 and five
CRISPR/cas9 TRPM4 knockout clones demonstrated that TRPM4 exhib-
ited large Na+ current densities (~ 60 pA/pF). In addition, CRISPR/cas9
TRPM4 knockout clones showed a tendency toward decreased migration
and invasion, cell viability, and proliferation and exhibited a shift in cell
cycle when compared to HCT116. Stable overexpression of TRPM4
(TRPM4 wild-type) in two CRISPR/cas9 TRPM4 knockout clones rescued
the decrease in cell viability and cell cycle shift. Stable overexpression of a
nonconducting, dominant-negative TRPM4 mutant (TRPM4 D894A) did
not rescue the decrease in viability or cell cycle shift. Taken together, these
findings pointed to TRPM4 ion channel conductivity as the underlying
mechanism for decreased viability and cell cycle shift in the TRPM4
knockout clones. Together with previous findings, our present data suggest
that TRPM4 plays a versatile role in cancer cell proliferation, cell cycle,
and invasion.
1. Introduction
In 2018, 1.8 million cases of colorectal cancer (CRC)
were registered worldwide and ~ 881 000 patients died
of CRC (World Health Organization, 2018). As in
other types of cancer, driver mutations in several key
signaling pathways promote CRC pathogenicity. In
particular, alterations in the PI3K, WNT, and KRAS
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CD, current density; CRC, colorectal cancer; TBC, tumor border configuration; TRPM4, transient receptor potential melastatin-4 channel.
1Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
34
96
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
pathways lead to increased migration and proliferation
of CRC cells (Dienstmann et al., 2017; Huang et al.,
2018). Emerging evidence reveals that ion channel mal-
functions within these pathways contribute to cancer
hallmark functions (Bose et al., 2015; Litan and Lang-
hans, 2015).
Transient receptor potential melastatin-4 channel
(TRPM4) is expressed in several human tissues (Lau-
nay et al., 2002; Nilius et al., 2003) and has been
identified as a cancer driver gene that contributes to
migration, proliferation, and invasion of prostate
cancer (PCa) cells (Berg et al., 2016; Holzmann
et al., 2015; Sagredo et al., 2018, 2019; Schinke
et al., 2014). In PCa, TRPM4 expression is nega-
tively regulated by microRNA-150, which results in a
shift in cell cycle to G1 phase (Hong and Yu, 2018).
The mechanism of TRPM4’s contribution to PCa
hallmark functions remains unclear. It may be based
on altered Ca2+ signaling, since Na+ influx via
TRPM4 can reduce the driving force for Ca2+ entry
(Barbet et al., 2008; Cheng et al., 2007; Holzmann
et al., 2015; Kilch et al., 2016; Shimizu et al., 2009).
Other reported mechanisms of action for TRPM4
include WNT pathway alterations, interactions of
TRPM4 with other proteins, and localization of
TRPM4 in the focal adhesome (Blanco et al., 2019;
Caceres et al., 2015; Gerzanich et al., 2018; Sagredo
et al., 2019). In prostate and cervical cancer cells,
TRPM4 contributes to proliferation by decreasing
Akt/GSK3-b activity and enhancing b-catenin signal-
ing in the WNT pathway (Armisen et al., 2011;
Sagredo et al., 2018). In contrast, public database
analysis identified TRPM4, together with six other
differentially expressed genes, as a good prognostic
marker for endometrial cancer (Liu et al., 2019). In
CRC, TRPM4 mRNA expression is reported to be
decreased (Sozucan et al., 2015) or not changed
(Perez-Riesgo et al., 2017). It has also been suggested
that TRPM4 may play a role in Ca2+-induced mucin
secretion from goblet cells (Cantero-Recasens et al.,
2019). The role of TRPM4 in CRC pathophysiology
has not been investigated.
Given the heterogeneous nature of cancerous tis-
sues, our study focuses on TRPM4 protein expres-
sion in CRC tissue instead of TRPM4 mRNA
expression. In the present study, we analyzed
TRPM4 protein expression levels in CRC tissue from
379 patients and examined its correlation with clini-
cal and tumor parameters. Furthermore, we investi-
gated TRPM4’s contribution to CRC cell
proliferation, viability, migration, invasion, cell cycle,
and TRPM4 ion conductivity as the possible under-
lying mechanism.
2. Materials and Methods
2.1. Patients and tissue microarray construction
This study included a retrospective collective of 379
patients who were diagnosed with primary CRC at the
Institute of Pathology, University of Bern, between
2002 and 2013. Table S1 presents the patient charac-
teristics. No patients received preoperative therapy.
Information regarding overall survival and postopera-
tive therapy was available for 378 patients. CRC sam-
ples were mounted onto next-generation Tissue
Microarrays (ngTMA, Zlobec et al., 2013). From all
corresponding tissue blocks, H&E-stained sections
were scanned and digitally annotated using a desig-
nated TMA annotation tool. Multiple areas were
marked, including regions from the tumor center (TC),
tumor invasion front, and tumor microenvironment
(TME). An average of 6–8 punches per CRC was
taken. The use of tissues and data in this study was
approved by the local ethics committee (Ref: 200/
2014). This study was conducted in accordance with
the guidelines set by the Declaration of Helsinki.
2.2. Immunohistochemistry
All ngTMA blocks were cut into 2.5-µm sections and
dried at 60 °C for 30 min. Immunohistochemistry was
performed using an automated immunostainer (Leica
Bond RX, Leica Biosystems, Nussloch, Germany).
After deparaffinization, antigen retrieval was performed
in citrate buffer at 100 °C for 30 min. Then, endogenous
peroxidase was blocked with H2O2 for 5 min. Samples
were incubated with TRPM4 rabbit antibody (1 : 200
dilution; generated by Pineda, Ozhathil et al., 2018) for
30 min and then with horseradish peroxidase-polymer
for 15 min. Visualization was performed using 3,3-di-
aminobenzidine as a brown chromogen (Bond Polymer
Refine Detection Kit, Leica Biosystems, Ref DS9800)
for 10 min. Finally, hematoxylin was applied for 5 min
to counterstain nuclei. Slides were scanned with Panno-
ramic 250 Flash II and photographed in CaseViewer
(3DHistech, Budapest, Hungary). Staining was homoge-
neous from punch to punch; thus, the intensity of each
core was evaluated and scored as either negative (no
epithelium showed immunoreactivity for the protein), 1
(weak intensity), or 2 (strong intensity). Each tissue
location was scored independently [TC, tumor front
(TF), and TME]. In tissues with more than one punch
per patient, median values were included in the statisti-
cal analysis. Descriptive statistics were used for TRPM4.
Chi-square test was performed to determine the
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association of expression with categorical variables
(Table S1), and a nonparametric Kruskal–Wallis test
was used for continuous variables. All P values are two-
sided, and P < 0.05 was considered statistically signifi-
cant. Analyses were performed using SAS V9.2 (The SAS
Institute, Cary, NC, USA) and GRAPHPAD PRISM 8
(GraphPad Software, San Diego, CA, USA).
2.3. Cell culture
All cell lines were cultured according to ATCC (Manas-
sas, VA, USA) guidelines. Standard growth medium sup-
plemented with 0.25 lgmL1 puromycin (Gibco,
Thermo Fisher, Waltham, MA, USA) was used for culti-
vation of cells with stable re-expression of TRPM4 wild-
type (WT), TRPM4 D984A, and GFP control construct.
2.4. Generation of HCT116 TRPM4 knockout
clones 1–5 by CRISPR/-Cas9 technique
Two different deletions were generated: deletion 1
(9744 bp, chromosome 19: 95 975–105 719) between
exons 2 and 4, and deletion 2 (454 bp, chromosome
19: 105 706–106 159) between exons 1 and 2. For each
deletion, two-guide RNAs were designed: gRNA,
gRNA4.1/gRNA4.2 for deletion 1 and gRNA50fw/
crRNA4 for deletion 2 (Heigwer et al., 2014). The
sense and antisense oligonucleotides for the gRNAs
(Table S2) were cloned into a pSpCas9(BB)-2A-GFP
vector (#48138; Addgene, Watertown, MA, USA) or a
pU6-(BbsI)-CBh-Cas9-T2A-mCherry vector (#64324;
Addgene). Cloning was performed as previously
described (ZhangLab). Transfection of HCT116 cells
was performed with the 4D Nucleofector (Lonza,
Basel, Switzerland) following the manufacturer’s
instructions. 2 9 106 cells were transfected with 2 µg
of each gRNA. At 24 h post-transfection, cells were
sorted for GFP/mCherry with ASTRIOS flow cytome-
try sorter (Beckman Coulter, Indianapolis, IN, USA).
Clones were screened by genotyping. Primers and pri-
mer pairs are listed in Tables S3 and S4. Five of the
145 clones tested showed the desired deletion in both
alleles (KO 1–4 deletion 1, KO 5 deletion 2).
2.5. Stable re-expression of TRPM4 WT and
TRPM4 D984A in TRPM4 KO 1–2 cells
Transient receptor potential melastatin-4 WT, domi-
nant-negative TRPM4 (D984A), and GFP control con-
structs were amplified from TRPM4-pMaxGFP and
TRPM4D984A-pMaxGFP vectors with primers listed
in Table S5 and S6. Primers were designed according to
ClonExpress Entry One Step Cloning Kit’s (Vazyme,
Nanjing, China) instruction. The upstream recombina-
tion sequence and the downstream recombination
sequence were designed to overlap with the piggyBac
vector (5753 bp) cut with BamHI and XhoI. The recom-
bination reaction was performed with ClonExpress
Entry One Step Cloning Kit, according to manufac-
turer’s guidelines. Transfection of TRPM4WT, TRPM4
D984A, and control vector was performed in KO 1 and
2 cells. Cells were cotransfected with corresponding pig-
gyBac vector and transposase vector with the use of
FuGENE transfection kit (Promega, Madison, WI,
USA). For selection, cell culture media was changed to
medium supplemented with 0.5 lgmL1 puromycin
(Gibco) 24–48 h after transfection. After 1–2 weeks, all
cells were positively transfected (green fluorescence). To
achieve similar levels of expression and remove cells
with highly overexpressed TRPM4, cells were further
sorted for GFP intensity with the ASTRIOS flow
cytometry sorter. Only cells showing low fluorescence
were used for further experiments.
2.6. Quantitative real-time PCR
Total RNA was isolated from HCT116 cell pellets
using the QIAshredder and the RNeasy Mini kit (Qia-
gen, Hilden, Germany). Reverse transcription was per-
formed with 2 µg RNA and the High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher). Diluted
cDNA (1 : 4) was used for qPCR with the TaqMan
Gene Expression Assay (Thermo Fisher). PCR condi-
tions were as follows: 2-min activation at 50 °C, then
10 min at 95 °C; followed by 40 cycles of 15-s denatu-
ration at 95 °C and 1-min annealing at 60 °C. Expres-
sion levels of target genes were normalized to
expression of the reference genes RNA polymerase II
(RNAPol II, Hs00172187_m1) and TATA-binding
protein (TBP, Hs00427621_m1). The detected target
sequences were TRPM4 Hs00214167_m1 (spans exons
12/13) and TRPM4 Hs01026061_m1 (spans exons 3/4).
2.7. Western blot analysis
Total protein lysate (50 µg) was separated on 10%
SDS/PAGE, and proteins were probed using rabbit
TRPM4 antibody (1 : 500; generated by Pineda,
Ozhathil et al., 2018) and mouse b-actin antibody
(1 : 2000; Cell Signaling Technology, Leiden, The
Netherlands, #3700). Antibodies and proteins were
detected with the LI-COR (LI-COR Biosciences, Lin-
coln, NE, USA) Odyssey Imaging System. Fluores-
cence of the secondary antibodies IRDye Donkey
anti-Mouse (#925-68022; LI-COR) and IRDye
800CW Goat anti-Rabbit (#925-32211; LI-COR) was
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quantified using LI-COR Image Studio Lite software.
TRPM4 expression was normalized to b-actin. Where
applicable, statistical significance was analyzed with
one-way ANOVA in GRAPHPAD PRISM 8.
2.8. Electrophysiology
Patch-clamp experiments were performed in a tight-seal
whole-cell configuration at 22–25 °C. Currents were
acquired with a HEKA EPC-10 amplifier, digitized,
and recorded with HEKA PATCHMASTER v2x53 (HEKA,
Lambrecht, Germany). Voltage ramps of 50-ms dura-
tion, spanning 100 to +100 mV from a holding poten-
tial of 0 mV, were delivered every 2 s over a 240-s
period. All voltages were corrected for a 10-mV liquid
junction potential. Capacitive currents were determined
and corrected before each voltage ramp delivery. Cur-
rents were filtered at 1 kHz and then sampled at 3 kHz.
For analysis, currents were extracted at 80 and
80 mV, normalized to cell capacitance and plotted ver-
sus time. Data were analyzed with IGOR PRO 6.37
(Wavemetrics, Lake Oswego, OR, USA). Bath solu-
tions contained 140 mM NaCl, 0.5 mM CaCl2, 3 mM
MgCl2, and 10 mM HEPES. In the N-methyl-D-glu-
camine (NMDG) bath solution, 140 mM NaCl was
replaced by 140 mM NMDG. pH was adjusted to 7.2
with NaOH or HCl. Osmolarity was adjusted to
~ 300 mOsm with glucose. Internal solution contained
140 mM Cs-glutamate, 10 mM EDTA, 10 mM HEPES,
and 8 mM NaCl. Concentrations of MgCl2 (3 mM) and
CaCl2 (10 µM) were adjusted according to WEBMAXC
STANDARD. Under these conditions, the patch pip-
ettes resistances were between 2 and 3 MΩ.
2.9. Cell viability
Cells were seeded in triplicates on 96-well plates at
1 9 104 cells per well in standard growth media. Assays
were performed using the RealTime-Glo MT Cell Via-
bility Assay kit (#G9711; Promega) according to the
manufacturer’s instructions. Luminescence intensity was
detected every hour over a 72-h period using a Tecan
SparkTM (Tecan, M€annedorf, Switzerland) 10 M multi-
mode microplate reader. For analysis, data for each
measurement were normalized to the first data point.
Statistical significance was analyzed using a Friedman
test and Dunn’s test for multiple comparisons.
2.10. 5-Fluorouracil (5-FU) viability assay
Cells were seeded in 96-well plates at 1 9 104 cells per
well in standard growth media. After ~ 6 h, cell cul-
ture medium was changed to standard growth medium
with NanoLuc Luciferase and MT Cell Viability Sub-
strate (Promega). To induce cell death, cells were trea-
ted with 10 or 50 µM 5-FU (#F6627; Sigma Aldrich,
St. Louis, MO, USA). Measurements with a final con-
centration of 0.02% DMSO were used as a control.
Cell viability was monitored over a 72-h period using
a Tecan SparkTM 10 M multimode microplate reader.
2.11. Proliferation
Proliferation was determined on xCELLigence (Acea
Biosciences, San Diego, CA, USA) E-Plates in an
xCELLigence RTCA DP system. 4 9 104 cells were
plated in standard growth medium and proliferation
was measured for 48 h in 15-min intervals. Statistical
significance was analyzed with Friedman test and
Dunn’s test for multiple comparisons.
2.12. Cell cycle analysis
To determine cell cycle distribution, propidium iodide
(PI; Abcam, Cambridge, UK) staining was performed
according to the manufacturer’s guidelines. PI staining
was detected with a BD LSR II BD flow cytometer and
FACSDIVA software (BD Biosciences, Franklin Lakes, NJ,
USA). Data analysis and statistical analysis (RM one-
way ANOVA and Holm–Sidak’s multiple comparison
test) were performed using FLOWJO10 (FlowJo, LLC,
Franklin Lakes, NJ, USA) and GRAPHPAD PRISM.
2.13. Migration and invasion
Migration and invasion assays were performed on
xCELLigence CIM-Plates in an xCELLigence
RTCA DP device according to the manufacturer’s
instructions. 4 9 104 cells/100 µL in serum-free med-
ium were seeded, and migration toward medium con-
taining 1 % FBS was measured at 15-min intervals for
48 h. To measure invasion, an additional Corning
Matrigel (LOT #7345017, 400 µgmL1) coating and
medium containing 10 % FBS as invasion stimulus
were used. Invasion data have been set to zero by sub-
traction of the cell index value at 24 h. Statistical sig-
nificance was analyzed by Friedman test and Dunn’s
multiple comparison test.
3. Results
3.1. Expression of TRPM4 in human CRC
Human normal and CRC tissue samples were stained
with a TRPM4-specific antibody in next-generation
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Tissue Microarrays (ngTMA; Fig. 1A). Figure S1
shows the specificity of the TRPM4 antibody: TRPM4
staining was detected in HCT116 cells, but not in
HCT116 TRPM4 knockout cells when cells were fixed
and stained using the same protocol as for the
ngTMA. TRPM4 staining intensities in the TC and
TF regions of CRC tissue, and in the TME, were digi-
tally recorded. Staining intensities were rated as nega-
tive (0), weak (1), or strong (2). Tumor characteristics
and clinical parameters were statistically analyzed
according to TRPM4 staining intensity (Table S1).
The heterogeneous front of CRC tissue is character-
ized by areas with pushing or expanding tumor
borders, and invasion sites exhibiting an infiltrative
growth pattern and disseminated cells. The tumor bor-
der configuration (TBC) parameter was defined as the
percentage of the pushing/infiltrating margin ratio. In
CRC, low TBC percentages are associated with tumor
invasiveness and higher tumor grades, lymphatic and
vascular invasion, shorter patient survival, and an
increased probability of lymph node metastasis
(Karamitopoulou et al., 2015). Figure 1B shows TBC
analysis according to TRPM4 staining intensity from a
Kruskal–Wallis test for nonparametric data. Strong
TRPM4 staining intensities (score of 2) were associ-
ated with significantly lower TBC values (for TC and
Fig. 1. TRPM4 in human CRC tissue. (A) Overview (upper panels) and close-up view (lower panels) of TRPM4 antibody staining of normal
tissue (left panels), tumor tissue (middle panels), and TME (right panels). Arrows indicate tumor buds in the TME (right panels). Upper part:
209 magnification, 50-µm scale bar. Lower part: 409 magnification, 20-µm scale bar. (B) Bar diagram (mean + SEM) of TBC ratio in %
plotted against TRPM4 staining intensities (I; negative, 0; weak, 1; strong, 2) from TC, TF, and TME. Numbers of biologically independent
replicates (n) are n = 56 for I = 0, n = 168 for I = 1, and n = 81 for I = 2 in TC; n = 64 for I = 0, n = 134 for I = 1, and n = 48 for I = 2 in
TF; and n = 43 for I = 0, n = 133 for I = 1, and n = 75 for I = 2 in TME. (C) Scatter plot of the numbers of tumor buds plotted against
TRPM4 staining intensities. Numbers of biologically independent replicates are n = 50 for I = 0, n = 103 for I = 1, and n = 38 for I = 2 in
TF; n = 48 for I = 0, n = 134 for I = 1, and n = 59 for I = 2 in TC; and n = 31 for I = 0, n = 102 for I = 1, and n = 62 for I = 2 in TME.
Red bars represent medians. Asterisks indicate statistically significant differences analyzed by a Kruskal–Wallis test (*P < 0.05, **P < 0.005,
****P < 0.0001) in B and C.
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TME staining), indicating that high TRPM4 protein
expression was associated with infiltrative growth pat-
terns.
Tumor budding is defined as the presence of dissem-
inated single CRC cells or small clusters of up to five
CRC cells, which are often found in the TME with
infiltrative growth patterns. CRC tumor budding is
commonly associated with invasive tumor growth,
epithelial–mesenchymal transition (EMT), and lym-
phovascular invasion (Georges et al., 2018; Koelzer
et al., 2016). CRC tissue characterized by higher
TRPM4 staining intensity was associated with signifi-
cantly more tumor buds in the TME (Fig. 1C).
Overall, high TRPM4 protein expression levels cor-
related with a high number of tumor buds, and an
infiltrative growth pattern (low percentage of TBC).
Both characteristics are associated with tumor invasion
and metastasis.
3.2. Expression of TRPM4 in CRC cells
While tumor nodes metastasis staging is the most com-
mon classification system for CRC, the Dukes system
can be used to classify CRC into four categories. In
Dukes stage A, cancer cells have invaded surrounding
tissues, but the tumor has not yet penetrated the bowel
wall. In Dukes stage B, cancer cells have invaded the
muscle layer by breaking through the bowel wall, but
lymph nodes are not involved. Dukes stage C indicates
additional involvement of the lymph nodes, and Dukes
stage D indicates CRC showing widespread metastasis.
Here, we investigated TRPM4 expression in a colon
cell line (CCD 841 CoN) and cancer cell lines
representing CRC in Dukes stage A (HCT116), B
(LS180), C (HCT15), and D (Colo205). In these cell
lines, TRPM4 mRNA levels were determined by qPCR
and normalized to two reference genes: TBP (Fig. 2A)
and RNA Pol II (data not shown). Figure 2B (left
panel) shows a representative western blot for TRPM4
protein expression in the different cell lines (normal
cells and Dukes stage A–D). TRPM4 was normalized
to b-actin. Figure 2B (right panel) shows the average
densitometry from three independent experiments.
TRPM4 expression was elevated in the Dukes stages
B, C, and D cell lines compared to normal cells, and
this elevation was significant in Dukes stage D CRC
cells.
3.3. Functional analysis of TRPM4 in HCT116 and
HCT116 TRPM4 knockout cells
We generated five different HCT116 TRPM4 knock-
out clones (KO 1–5) with CRISPR/cas9 technique.
Analysis by qPCR and western blot confirmed the
absence of TRPM4 mRNA and protein expression
(Fig. S2 and Fig. 3A). We assessed TRPM4 ion
channel activity by whole-cell patch-clamp technique
and found that 10 µM Ca2+ in the patch pipette acti-
vated ICAN (Ca
2+-activated nonselective current) in
HCT116. Currents at 80 and +80 mV were nor-
malized to cell capacitance (proportional to cell
size), and we plotted the average current density
(CD) versus time (Fig. 3B). Under these conditions,
we detected a CD of 60 pA/pF, compared to a
value of 40 pA/pF in PCa cells (Holzmann et al.,
2015). Replacement of external Na+ in the bath
Fig. 2. TRPM4 expression in CRC cells representing Dukes stages A–D. (A) TRPM4 mRNA levels in CCD 841 CoN (normal colon cells),
HCT116 (Dukes stage A), LS180 (Dukes stage B), HCT15 (Dukes stage C), and Colo205 (Dukes stage D) normalized to TBP. The results
from three independent experiments are presented as mean + SEM. (B) Representative western blot from CCD 841 CoN, HCT116, LS180,
HCT15, and Colo205 cells (left panel). TRPM4 was detected with an anti-TRPM4 antibody. b-Actin was used as loading control and probed
with an anti-b–actin antibody. Quantification of protein expression levels shown as mean + SEM in CCD 841 CoN, HCT116, LS180, HCT15,
and Colo205 cells analyzed from three independent experiments (right panel). TRPM4 protein expression is normalized to expression of b-
actin. Statistical significance was analyzed with one-way ANOVA (**P < 0.005).
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solution by impermeable cation NMDG reversibly
inhibited inward currents pointing to monovalent
Na+ as inwardly conducted ion. This current devel-
opment is absent in KO 1–5. In conclusion, the
molecular basis of ICAN in HCT116 cells is TRPM4.
We did not observe any compensatory mechanisms,
for example through TRPM5 in any of the HCT116
KO cells. Figure 3C shows a linear current–voltage
relationship (IV) extracted from measurements in
Fig. 3B. The IV exhibits a slightly positive reversal
potential characteristic of TRPM4.
Overall, our results indicate that TRPM4 protein
was expressed and conducted large Na+ currents in
HCT116 cells. No compensatory mechanism was
observed in patch-clamp experiments with five differ-
ent HCT116 TRPM4 knockout clones (KO 1–5).
3.4. Function of TRPM4 in CRC cells
We next assessed the role of TRPM4 in cell viability
by performing a real-time kinetic viability assay
(Fig. 3D). After 48 h, cell viability was reduced in KO
Fig. 3. TRPM4 knockout (KO) and cancer hallmark functions in HCT116. (A) Western blot analysis from HCT116 and KO 1–5. Protein
expression levels were detected using anti-TRPM4 and anti-b-actin. (B) ICAN was evoked with 10 µM Ca
2+ in the patch pipette. Data are
shown as mean  SEM and numbers of biologically independent replicates are n = 6 for HCT116, n = 4 for KO 1, n = 4 for KO 2, n = 3 for
KO 3, n = 3 for KO 4, and n = 3 for KO 5. (C) Corresponding IVs at 196 s from cells in B. (D) Cell viability was evaluated using a RealTime-
Glo MT assay. Mean of relative luminescence was plotted versus time. Three independent experiments were performed. (E) Bar diagram of
data (mean + SEM) at 24 h and 48 h from the experiments in D. (F) Cell proliferation was determined with an xCELLigence system. Mean
of cell index was plotted versus time. Three independent experiments were performed. (G) Bar diagram of data (mean + SEM) at 24 and
48 h from the experiment in F. (H) Mean of cell index of HCT116 cells and KO 1–5 in a migration assay plotted versus time. Each curve
represents an average of at least three independent experiments (n = 9 for HCT116, n = 4 for KO 1, n = 5 for KO 2, n = 7 for KO 3, n = 5
for KO 4, and n = 7 for KO 5). (I) Bar diagram of data (mean + SEM) extracted at 12 h and 14 h from the experiments in H. (J) Mean of cell
index of HCT116 cells and KO 1–5 in an invasion assay plotted versus time. Each curve represents an average of at least three independent
experiments (n = 9 for HCT116, n = 4 for KO 1, n = 5 for KO 2, n = 7 for KO 3, n = 5 for KO 4, and n = 7 for KO 5). (K) Bar diagram of
data (mean + SEM) extracted at 48 h and 60 h from experiments in J. Statistical analysis was performed using Friedman’s test with Dunn’s
multiple comparison (*P < 0.05, **P < 0.005) in E, G, I, and K.
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1–5 (8–37 %) compared to normal HCT116 cells
(Fig. 3E) and this decrease was significant in KO 1–2.
Cell proliferation was measured using an xCELLi-
gence RTCA DP system that allows label-free real-
time measurements. Based on electrical impedance, a
cell index reflecting cell number, size, and adhesion
was determined (Dowling et al., 2014) and plotted ver-
sus time (Fig. 3F). After 48 h, proliferation was
decreased in KO 1–4 (10–52%) and this decrease was
significant in KO 3 (Fig. 3G). KO 5 exhibited the
same proliferation as HCT116. In contrast, we found
no considerable difference in 5-fluorouracil-induced
cell death between HCT116 and KO 1–5 (Fig. S3).
Migration and invasion were tested using migration
plates in an xCELLigence RTCA DP system and
plotted as cell index versus time (Fig. 3H–K) (Dowling
et al., 2014). For invasion, cell plates were precoated
with Matrigel. In four of the five KO cell lines, we
detected decreased migration (6–51%, Fig. 3H), which
was significant after 14 h in KO 1 (Fig. 3I). Migration
of KO 3 was not decreased compared to HCT116.
Invasion was decreased in all five TRPM4 KO cells
(14–58%, Fig. 3J,K). Overall, our findings show that
TRPM4 knockout clones tend to have a lower viability
and proliferation compared to HCT116. In addition,
our data suggest that TRPM4 contributes to migration
and invasion of CRC cells.
3.5. TRPM4 ion conductivity in cancer hallmark
functions
Next, we investigated if cancer hallmark functions are
directly dependent on TRPM4 ion channel conductiv-
ity. Functional TRPM4 (TRPM4 WT) and a noncon-
ducting, dominant-negative mutant of TRPM4
(TRPM4 D984A, Nilius et al., 2005) were stably
expressed in HCT116 TRPM4 knockout cells (KO 1–
2). Re-expression of TRPM4 in KO 1–2 was confirmed
by qPCR (Fig. S4A) and western blot analysis (KO 1
in Fig. 4A and KO 2 in Fig. 4D). In both, KO 1–2
TRPM4 WT re-expression restored TRPM4 currents,
while TRPM4 KO cells expressing TRPM4 D984A
failed to conduct Na+ (KO 1 in Fig. 4B,C, KO 2 in
Fig. 4E,F).
In KO 1 and KO 2, re-expression of functional
TRPM4 reversed the tendency toward decreased via-
bility, while expression of TRPM4 D984A did not
have a rescuing effect on cell viability (KO 1 in
Fig. 4G,H and KO 2 in Fig. 4I,J). Rescue experiments
for other cellular functions (proliferation, migration,
and invasion) were less conclusive (Fig. S4B–G).
In summary, TRPM4 contributes to cancer cell via-
bility due to its ion conductivity.
3.6. TRPM4 ion conductivity in cell cycle
Changes in cell viability can be accompanied or caused
by changes in cell cycle and TRPM4 has been reported
to alter cell cycle in the past (Sagredo et al., 2018).
Indeed, all five TRPM4 KO cells were more likely to
be in G1 phase and less likely to be in G2 phase in
comparison with HCT116 (Fig. 5A, an exemplary
FACS analysis is shown in Fig. 5B). These results were
in line with previous work from Hong and colleagues
(Hong and Yu, 2018).
Both, KO 1 and 2 with re-expressed TRPM4 WT,
showed similar cell cycle patterns as HCT116 cells
(Fig. 5C,D), while expression of TRPM4 D984A failed
to rescue cell cycle changes (Fig. 5C,D). In conclusion,
TRPM4 ion conductivity is the underlying mechanism
for TRPM4 induced changes in cell cycle.
4. Discussion
Our present data demonstrated that TRPM4 protein
was expressed in CRC tumor tissue. Analysis of tumor
features from 379 patients revealed that high levels of
TRPM4 protein were related to aggressive tumor fea-
tures, including high numbers of tumor buds—which
is a sign of EMT, metastasis, and more aggressive
infiltrative growth patterns in CRC (Fig. 1) (Georges
et al., 2018; Karamitopoulou et al., 2015; Koelzer
et al., 2016). TRPM4 contributes to migration in mul-
tiple cellular systems, including immune cells, vascular
endothelial cells, and PCa cells (Barbet et al., 2008;
Holzmann et al., 2015; Sagredo et al., 2019; Sarmiento
et al., 2015; Shimizu et al., 2009). In CRC cells
(HCT116), TRPM4 knockout resulted in reduced
migration and invasion (Fig. 3).
In cell lines representing Dukes stages A–D,
TRPM4 protein expression levels suggested that high
TRPM4 protein expression levels were associated with
CRC metastasis (Dukes stage D; Fig. 2). This indicates
that TRPM4’s contribution to migration and invasion
may be even more prominent in late-stage CRCs.
Notably, in Colo205 (Dukes stage D) TRPM4 protein
levels were high, while mRNA levels were rather low.
This could be due to post-translational mechanisms
that are altered in cancer cells and affect TRPM4
function, for example, glycosylation (Syam et al.,
2014). The imbalance of mRNA versus protein level in
Colo205 may also reflect that while TRPM4 mRNA
expression in CRC is decreased (Sozucan et al., 2015),
we find high TRPM4 protein expression correlated
with tumor budding and TBC.
Overall, our data highlight a functional role of
TRPM4 in tumor cell migration and invasion, which
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Fig. 4. TRPM4 rescue in KO 1 and KO 2. (A) Western blot analysis of KO 1 + TRPM4 WT, KO 1 + TRPM4 D984A, and KO 1 + control
(empty vector). (B) ICAN was evoked with 10 µM Ca
2+ in the patch pipette. Data are shown as mean  SEM, and numbers of biologically
independent replicates are n = 6 for KO 1 + TRPM4 WT, n = 4 for KO 1 + TRPM4 D984A and n = 8 for KO 1 + control. (C) IVs from cells
in B at t = 196 s. (D) same as A for KO 2. (E) Same as B for KO 2. Data are shown as mean  SEM, and numbers of biologically
independent replicates are n = 7 for KO 2 + TRPM4 WT, n = 4 for KO 2 + TRPM4 D984A and n = 5 for KO 2 + control. (F) IVs from cells
in E at t = 196 s. (G) Mean of cell viability in KO 1 + TRPM4 WT, KO 1 + TRPM4 D984A, and KO 1 + control. (H) Bar diagram of data
(mean + SEM) at 24 and 48 h from three independent experiments in G. (I) Mean of cell viability in KO 2 + TRPM4 WT (n = 3), KO
2 + TRPM4 D984A (n = 3), and KO 2 + control (n = 3). (J) Bar diagram of data (mean + SEM) at 24 and 48 h from three independent
experiments in I. Statistical significance was tested by a Friedman test and Dunn’s multiple comparison test. (*P < 0.05) in H and J.
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may contribute to tumor budding. This could either be
due to an impairment of chemotaxis (steering mecha-
nism) or migration (motor mechanism). Different
mechanisms have been proposed for how TRPM4 con-
tributes to cell migration, such as alteration of Ca2+
signaling, and alteration of the APC pathway (Caceres
et al., 2015; Holzmann et al., 2015; Sagredo et al.,
2019; Shimizu et al., 2009). Alterations in the APC-
WNT/b-catenin, transforming growth factor-b, EGFR,
and downstream MAPK and PI3K signaling pathways
are nearly ubiquitous events in CRC. In ~ 80% of
tumors, APC gene defects result in constitutive WNT
signaling and protein expression of b-catenin-activated
genes, such as matrix metalloproteinases (MMPs), con-
tributing to EMT (Fearon, 2011).
SNAIL1 is a protein within the APC pathway,
which suppresses synthesis of E-cadherin, an adhesion
protein that prevents EMT and promotes expression
of MMPs. TRPM4 functionally contributes to EMT
by regulation of SNAIL1 expression levels in PCa cells
(Sagredo et al., 2019). Further research is needed to
investigate whether there is a coherent mechanism for
TRPM4 in CRC. Notably, APC dysfunction (e.g.,
nuclear translocation of b-catenin) and SNAIL1
expression have also been discussed in the context of
tumor budding, as b-catenin, SNAIL1, and MMP
expression levels are elevated in tumor buds (Galvan
et al., 2015; Jass et al., 2003; Zlobec and Lugli, 2010).
Transient receptor potential melastatin-4 knockout
cells were characterized by lower viability, lower prolif-
eration, and a cell cycle shift to G1 phase (Figs 3 and
5). These findings are in line with data from PCa cells
(Hong and Yu, 2018), as TRPM4 inhibition by micro-
RNA-150 regulates cell cycle and proliferation via a
cell cycle shift toward G1. Additionally, Ricardo
Armisen’s group demonstrated that TRPM4 regulates
cell cycle progression. Knockdown of TRPM4 results
in increased degradation of b-catenin, and a Ca2+-de-
pendent decrease in GSK-3b activity and decreased
expression of proliferation-associated genes (Sagredo
Fig. 5. FACS-based cell cycle analysis. (A) Bar diagram (mean + SEM) for cell cycle distribution of HCT116 and KO 1–5 from five different
experiments. (B) Representative histograms of PI staining in HCT116, KO 1, KO 1 + TRPM4 D984A, and KO 1 + control. (C) Bar diagram
(mean + SEM) of cell cycle distribution of HCT116, KO 1, and KO 1 + TRPM4 WT, KO 1 + TRPM4 D984A, and KO 1 + control for eight
independent experiments each. (D) Bar diagram (mean + SEM) of cell cycle distribution of HCT116, KO 2, and KO 2 + TRPM4 WT, KO
2 + TRPM4 D984A, and KO 2 + control for eight independent experiments each. RM one-way ANOVA and Holm–Sidak’s multiple
comparison test were used to determine statistical significance (*P < 0.05, **P < 0.005, ***P < 0.0005) in A, C and D.
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et al., 2018). Notably, an siRNA-based screening assay
points to TRPM4 as a regulator of the WNT-b catenin
signaling pathway in CRC cells (Major et al., 2008).
In our present study, patch-clamp analysis demon-
strated that CRC cells from Dukes stage A (HCT116)
exhibited endogenous TRPM4 currents of ~ 60 pA/pF
(Fig. 3). This exceeds the currents detected in other
cellular systems (TRPM4 currents are ~ 40 pA/pF in
PCa cells, Holzmann et al., 2015). We find strong evi-
dence that cell viability and cell cycle shift depend on
TRPM4 ion conductivity (Figs 4 and 5). Future inves-
tigations will show how TRPM4 ion conductivity
alters cell viability and cell cycle. Na+ influx via
TRPM4 has been shown to alter Ca2+ signaling (Bar-
bet et al., 2008; Cheng et al., 2007; Holzmann et al.,
2015; Kilch et al., 2016; Nilius et al., 2003; Shimizu
et al., 2009). Hence, one explanation can be that
TRPM4 alters Ca2+ signaling important for cell viabil-
ity and cell cycle in CRC. Taken together, our study
finds a multifaceted, pathophysiological role for
TRPM4 in CRC, highlighting TRPM4 as a putative
therapeutic target in CRC therapy.
5. Conclusion
High TRPM4 protein expression in CRC is correlated
with unfavorable tumor features (a high number of
tumor buds, and a low TBC), associated with EMT,
metastasis, and invasion. Investigation of cell functions
in CRC cells with TRPM4 knockout suggests that
TRPM4 adds to invasion—one of the initial steps to
metastasis. TRPM4 ion conductivity contributes to cell
viability and shifts cell cycle to G2 phase. Together
with previous findings, the prominence of TRPM4 in
CRC pathophysiology suggests a versatile role for
TRPM4 in different types of cancer.
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